Meeting
2022 ASCO Genitourinary Cancers Symposium
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
Authors
Karim Fizazi
Gustave Roussy and University of Paris-Saclay, Villejuif, France
Karim Fizazi , Natalie Cook , Philippe Barthélémy , Alice Bernard-Tessier , Capucine Baldini , Niamh Peters , Pirjo Nykänen , Tarja Ikonen , Pasi Pohjanjousi , Leena Mattila , Lauri Jouhi , Annamari Vuorela , Chris Garratt , Tapio Utriainen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03436485
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 18)
DOI
10.1200/JCO.2022.40.6_suppl.018
Abstract #
18
Poster Bd #
A3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2018 Genitourinary Cancers Symposium
AR-V7 in Asian patients with metastatic CRPC: A multinational, multicentre study.
First Author: Hui Shan Tan
Poster
2015 Genitourinary Cancers Symposium
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis